Mouse models of polyglutamine diseases: review and data table. Part I - Wikidata - wikimedia - TriplyDB

Mouse models of polyglutamine diseases: review and data table. Part I

Mouse models of polyglutamine diseases: review and data table. Part I

http://www.wikidata.org/entity/Q26853025

about

sameAs

RNA-mediated pathogenic mechanisms in polyglutamine diseases and amyotrophic lateral sclerosis Oligonucleotide-based strategies to combat polyglutamine diseases.C-terminal domain swapping of SSB changes the size of the ssDNA binding site The role for alterations in neuronal activity in the pathogenesis of polyglutamine repeat disorders.Mouse polyQ database: a new online resource for research using mouse models of neurodegenerative diseases.Mechanisms mediating spinal and bulbar muscular atrophy: investigations into polyglutamine-expanded androgen receptor function and dysfunction.RNA toxicity in polyglutamine disorders: concepts, models, and progress of research Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis.Induced Pluripotent Stem Cells in Huntington's Disease: Disease Modeling and the Potential for Cell-Based Therapy.Pharmacological protein targets in polyglutamine diseases: mutant polypeptides and their interactors.Inflammation in neurodegenerative diseases--an update.Striatal cholinergic interneurons in isolated generalized dystonia-rationale and perspectives for stem cell-derived cellular models.Animal models of Huntington's disease for translation to the clinic: best practices.Prion-Like Characteristics of Polyglutamine-Containing Proteins.Proteins Containing Expanded Polyglutamine Tracts and Neurodegenerative Disease.

P2860

Q28082520-410FD5D3-16AC-4DB9-AD57-42D1350DC725 Q33791247-CFBCF2F0-E975-4BD0-9EB2-E5AC34DB27F1 Q34064949-0CBC3480-9981-421D-A6EA-82AE9DA5CAA6 Q35340099-8CAA6DC6-0DAE-4B10-9C72-40D2EF102DAA Q36222731-4E3C91C5-B1DF-419D-9087-FDC0C7E83DA5 Q36844932-E8D1ABA8-10BE-4CBC-A62B-6971F76B4D2D Q36859984-FD8859E2-8D1B-43AE-8146-05FAAA4A822C Q37165188-F3F8D9E4-363E-452F-969E-DA188DF18D53 Q37652595-C398162F-5420-4FF6-B89D-0B27B47BD512 Q38107677-6EF225FA-0DC2-45AE-9A8E-B359EE0A902D Q38170472-CBE183D3-0DFB-4E93-9A34-20F6B4472E3D Q38239643-CE1B1E0F-FF24-4F66-9622-1F79D05AC156 Q38248687-14221AC6-D9A0-4DE2-A9E0-F99DD71D56A0 Q39092630-82AAA1D4-6662-4EF0-9590-7DBC599C14F5 Q39124557-7D3C9D1E-AAA9-4AB7-BA98-BB2D600DF7DD

P2860

Mouse models of polyglutamine diseases: review and data table. Part I

http://www.wikidata.org/entity/Q26853025

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Mouse models of polyglutamine diseases: review and data table. Part I

@ast

Mouse models of polyglutamine diseases: review and data table. Part I

@en

Mouse models of polyglutamine diseases: review and data table. Part I

@nl

type

label

Mouse models of polyglutamine diseases: review and data table. Part I

@ast

Mouse models of polyglutamine diseases: review and data table. Part I

@en

Mouse models of polyglutamine diseases: review and data table. Part I

@nl

prefLabel

Mouse models of polyglutamine diseases: review and data table. Part I

@ast

Mouse models of polyglutamine diseases: review and data table. Part I

@en

Mouse models of polyglutamine diseases: review and data table. Part I

@nl

P1433

Q26853025-0B6D5F82-F076-46AF-9865-400B9835C4AF

P1476

Q26853025-BDA6B12A-8E1B-4A83-9CDD-8562A50B3319

P2093

Q26853025-11BABD76-77E1-4149-B272-80438E31C3A2

Q26853025-A51168AA-AAD3-4266-B39A-C5D0098ACC95

P2860

Q26853025-00E70877-8A43-43BA-896C-F34D160E4EB1

Q26853025-0114EB3E-BA4D-4D2C-90CE-976246D0E43F

Q26853025-01240908-5A84-4D42-B746-058BF138FD3C

Q26853025-013946E4-B737-4591-AD09-CF286A0D3F16

Q26853025-0196B71A-A1E6-4484-895A-521E675434CC

Q26853025-022F031B-1915-4FBA-870A-7073B5CD2E06

Q26853025-031FD617-5226-4351-B2FF-63EE334DD908

Q26853025-06BFF0CB-BE55-4591-84D6-FB6611BAAB3B

Q26853025-075302BD-931A-45A5-844C-3C534864B1EF

Q26853025-0788B2F7-AC99-4CD4-9A26-8F486E5321AD

P2888

Q26853025-7DC64CE2-32D7-47BE-95E9-4FAE3EE6B2E9

P304

Q26853025-2F433A5F-6DCD-439A-9DFD-5E6F7564604E

P31

Q26853025-9D753E6C-7620-4C4C-88E1-D185ADD58BCB

Q26853025-D20EC548-C060-4BA2-80F5-78805187E904

P356

Q26853025-CC95CA30-88ED-45D6-BFF2-CC1B33D6BFE0

P407

Q26853025-B22FD0E1-0C55-452B-9F27-BB8B42AD4311

P433

Q26853025-1C19FD19-C065-4D72-9BFF-CEE305F7DC4D

P478

Q26853025-AC52C3D2-8CC6-40F3-81B9-CD9328D7CD42

P50

Q26853025-6E5C754F-2814-4237-8BE9-77EBBE39E3D8

Q26853025-BB984F2D-9A62-4DC7-8DF1-F5586EC3865C

Q26853025-DE9DDA1B-2C08-4FDA-A329-F20C174BB5DE

P577

Q26853025-9B02E8A6-9528-4AF5-BDE9-D2D748D4538C

Q26853025-FA4E050C-AE6D-44B5-9032-6C815AC70030

P5875

Q26853025-A5213AB6-596B-4F44-B496-F492D0D98DA3

P6179

Q26853025-3A3FFB9A-0880-4AA9-B591-5B459861EF19

P698

Q26853025-63B25A30-0917-4C66-AF02-594B4FE57983

P921

Q26853025-3A7F745B-4D0A-4ECD-A537-520D1E95FBE5

Q26853025-A3B0423F-7C56-4D1E-AAD2-D9F80BEFFACB

Q26853025-BED600BE-55A0-4586-A56C-AAF3AAA7CFCE

P932

Q26853025-7DC27D90-092E-4B59-A19D-1292E69883DC

P356

S12035-012-8315-4

P1433

Molecular Neurobiology

P1476

Mouse models of polyglutamine diseases: review and data table. Part I

@en

P2093

Agnieszka Gabka

http://www.w3.org/2001/XMLSchema#string

Pawel M Switonski

http://www.w3.org/2001/XMLSchema#string

P2860

Early alterations of brain cellular energy homeostasis in Huntington disease models

Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human

RORalpha-mediated Purkinje cell development determines disease severity in adult SCA1 mice

Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures

A natural antisense transcript at the Huntington's disease repeat locus regulates HTT expression

Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease

Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease

Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model

Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice

Glutamine-expanded ataxin-7 alters TFTC/STAGA recruitment and chromatin structure leading to photoreceptor dysfunction.

P2888

s12035-012-8315-4

P304

393-429

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12035-012-8315-4

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

Wojciech J Szlachcic

Włodzimierz Krzyżosiak

P577

2012-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232724814

http://www.w3.org/2001/XMLSchema#string

P6179

1016667475

http://www.w3.org/2001/XMLSchema#string

P698

22956270

http://www.w3.org/2001/XMLSchema#string

P921

neurodegeneration

biomedical investigative technique

P932

3461215

http://www.w3.org/2001/XMLSchema#string